Patents by Inventor Brendan Magrab

Brendan Magrab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FOSPROPOFOL METHODS AND COMPOSITIONS
    Publication number: 20230277567
    Abstract: The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.
    Type: Application
    Filed: February 15, 2023
    Publication date: September 7, 2023
    Inventors: Steven L. Krill, Feng-Jing Chen, Michael A. Rogawski, Edward Brendan Magrab, Allen H. Heller
  • Fospropofol methods and compositions
    Patent number: 11628178
    Abstract: The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: April 18, 2023
    Assignee: Epalex Corporation
    Inventors: Steven L. Krill, Feng-Jing Chen, Michael A. Rogawski, Edward Brendan Magrab, Allen H. Heller
  • PROPOFOL PRODRUG METHODS AND COMPOSITIONS
    Publication number: 20230084521
    Abstract: The present disclosure pertains to the use of propofol prodrugs, pharmaceutically acceptable salts of propofol prodrugs, or mixtures thereof, to treat migraine.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 16, 2023
    Inventors: Michael A. Rogawski, Enrique Carrazana, Edward Brendan Magrab, Steven L. Krill, Allen H. Heller
  • FOSPROPOFOL METHODS AND COMPOSITIONS
    Publication number: 20220265686
    Abstract: The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.
    Type: Application
    Filed: March 4, 2022
    Publication date: August 25, 2022
    Inventors: Steven L. Krill, Feng-Jing Chen, Michael A. Rogawski, Edward Brendan Magrab, Allen Heller
  • FOSPROPOFOL METHODS AND COMPOSITIONS
    Publication number: 20220105111
    Abstract: The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, to treat migraine.
    Type: Application
    Filed: March 26, 2020
    Publication date: April 7, 2022
    Inventors: Michael A. Rogawski, Enrique Carrazana, Edward Brendan Magrab, Steven L. Krill, Allen H. Heller
  • PROPOFOL PRODRUG METHODS AND COMPOSITIONS
    Publication number: 20220105050
    Abstract: The present disclosure pertains to the use of propofol prodrugs, pharmaceutically acceptable salts of propofol prodrugs, or mixtures thereof, to treat migraine.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 7, 2022
    Inventors: Michael A. Rogawski, Enrique Carrazana, Edward Brendan Magrab, Steven L. Krill, Allen Heller
  • COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH
    Publication number: 20210128665
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Application
    Filed: December 30, 2020
    Publication date: May 6, 2021
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, JR.
  • COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH
    Publication number: 20200054707
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe
  • Compositions and methods to inhibit kidney stone growth
    Patent number: 10471115
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 12, 2019
    Assignee: KIDNEY STONE RESEARCH COMPANY, INC.
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
  • COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH
    Publication number: 20180008660
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Application
    Filed: September 20, 2017
    Publication date: January 11, 2018
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
  • Compositions and methods to inhibit kidney stone growth
    Patent number: 9789152
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 17, 2017
    Assignee: KIDNEY STONE RESEARCH COMPANY, INC.
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
  • COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH
    Publication number: 20170216388
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, JR.
  • Compositions and methods to inhibit kidney stone growth
    Patent number: 9623066
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: April 18, 2017
    Assignee: KIDNEY STONE LABORATORIES, INC.
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
  • COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH
    Publication number: 20170065657
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Application
    Filed: December 7, 2015
    Publication date: March 9, 2017
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, JR.
  • COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH
    Publication number: 20170065658
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Application
    Filed: September 15, 2016
    Publication date: March 9, 2017
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, JR.
  • Compositions and methods to inhibit kidney stone growth
    Patent number: 9492491
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 15, 2016
    Assignee: KIDNEY STONE LABORATORIES, INC.
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
  • Compositions and methods to inhibit kidney stone growth
    Patent number: 9233135
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: January 12, 2016
    Assignee: KIDNEY STONE LABORATORIES, INC.
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
  • CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF
    Publication number: 20080292695
    Abstract: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.
    Type: Application
    Filed: December 3, 2007
    Publication date: November 27, 2008
    Inventors: Kristin Arnold, E. Brendan Magrab, David F. Erkoboni, Zhongshui Yu, Siva Rama K. Nutalapati, Rakeshkumar K. Lad